Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APPAC II: Optimizing antibiotic treatment of uncomplicated acute appendicitis
2024-518984-36-00Phase 4Authorised
- Sponsor
- Turku University Hospital
- Start
- Nov 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of levofloxacin, ertapenem, moxifloxacin and metronidazole in appendicitis (2 arms), sponsored by Turku University Hospital. Primary endpoint: Treatment success at one year. Planned start Nov 2024; status: authorised.
02
Drugs
levofloxacinertapenemmoxifloxacinmetronidazole
03
Conditions
appendicitis
Beyond the preview
Go deeper on 2024-518984-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518984-36-00.